CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 3, 2026
52W-Spanne
$29–$85
100% of range
Analystenbewertung
HOLD
21 analysts
Kursziel
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Nettogewinnmarge
-6046.2%
Über Crinetics Pharmaceuticals, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Mehr lesen
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
CRNX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$84.77
Marktkapitalisierung
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Umsatz (TTM)
$8M
Dividendenrendite
—
ROE
-43.0%
Verschuldungsgrad
—
52W-Spanne
$29 – $85
CRNX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
Freier Cashflow
$-384M
2018-12-31
→
2025-12-31
Margen
-6046.2%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
CRNX
Peer-Median
P/E (TTM)
-17.1
47.9
P/S (TTM) (K/V (TTM))
1052.7
16.2
P/B (K/B)
8.2
9.3
Price / FCF (Kurs / FCF)
-21.1
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
CRNX
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-6714.8%
—
Net Profit Margin (Nettogewinnmarge)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
CRNX
Peer-Median
Current Ratio (Liquiditätsgrad)
12.3
2.7
Quick Ratio
12.1
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
CRNX
Peer-Median
Revenue YoY (Umsatz YoY)
640.7%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
17.6%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
155.3%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
CRNX
Peer-Median
CRNX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
HALTEN
21 Analysten
- Starker Kauf 3 14,3%
- Kauf 4 19,0%
- Halten 14 66,7%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
10 Analysten · 2026-08-13
Median
$85.00
Mittelwert
$85.50
← Unter allen Zielen
$84.77
Tief
$85.00
Hoch
$90.00
Median-Ziel
$85.00
+0,3%
Mittelwert-Ziel
$85.50
+0,9%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.01%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-1.14 | $-1.23 | 0.09% |
| 31. März 2026 | $-1.23 | $-1.26 | 0.03% |
| 31. Dezember 2025 | $-1.29 | $-1.39 | 0.10% |
| 30. September 2025 | $-1.38 | $-1.28 | -0.10% |
| 30. Juni 2025 | $-1.23 | $-1.12 | -0.11% |
| 31. März 2025 | $-1.04 | $-0.96 | -0.08% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Bilanz 24
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Cashflow 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Bilanz 23
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Rentabilität 6
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $8M | $1M | $4M | $5M | $1M |
| Betriebsgewinnmarge % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Nettoergebnis | $-465M | $-298M | $-215M | $-164M | $-108M |
| Verwässerte EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-384M | $-230M | $-171M | $-117M | $-89M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 286 Einreicher · $3.2B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 63 (+17 vs. Vorquartal) | 30 (-14 vs. Vorquartal) | 95 (-17 vs. Vorquartal) | 63 (+3 vs. Vorquartal) | +21.6M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $486.250.673 | 12.994.406 | 15,13% | Aktien |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336.372.047 | 8.989.098 | 10,46% | Aktien |
| Driehaus Capital Management LLC | $241.866.078 | 6.463.551 | 7,52% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $237.002.526 | 6.333.579 | 7,37% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180.836.416 | 4.832.614 | 5,63% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $177.567.704 | 4.745.262 | 5,52% | Aktien |
| STATE STREET CORP | $100.635.477 | 2.689.350 | 3,13% | Aktien |
| Bellevue Group AG | $98.040.400 | 2.620.000 | 3,05% | Aktien |
| BAKER BROS. ADVISORS LP | $87.991.820 | 2.351.465 | 2,74% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $87.542.675 | 2.338.905 | 2,72% | Aktien |
| Polar Capital Holdings Plc | $85.108.460 | 2.274.411 | 2,65% | Aktien |
| Pictet Asset Management Holding SA | $77.572.984 | 2.075.375 | 2,41% | Aktien |
| Siren, L.L.C. | $53.165.887 | 1.420.788 | 1,65% | Aktien |
| First Light Asset Management, LLC | $50.923.606 | 1.360.866 | 1,58% | Aktien |
| NOVO HOLDINGS A/S | $49.394.400 | 1.320.000 | 1,54% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $47.245.129 | 1.262.562 | 1,47% | Aktien |
| ADAR1 Capital Management, LLC | $45.730.234 | 1.222.080 | 1,42% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $44.555.208 | 1.190.679 | 1,39% | Aktien |
| MONTANOVA CAPITAL, LLC | $44.390.560 | 1.186.279 | 1,38% | Aktien |
| ORBIMED ADVISORS LLC | $37.382.580 | 999.000 | 1,16% | Aktien |
| Hood River Capital Management LLC | $36.259.830 | 968.996 | 1,13% | Aktien |
| GOLDMAN SACHS GROUP INC | $34.657.132 | 926.166 | 1,08% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32.841.401 | 877.643 | 1,02% | Aktien |
| Aberdeen Group plc | $30.699.181 | 820.395 | 0,95% | Aktien |
| Candriam S.C.A. | $30.618.690 | 819.032 | 0,95% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $28.230.995 | 754.436 | 0,88% | Aktien |
| Fisher Asset Management, LLC | $27.748.912 | 741.553 | 0,86% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17.709.036 | 479.400 | 0,55% | Aktien |
| AMERIPRISE FINANCIAL INC | $17.451.149 | 466.356 | 0,54% | Aktien |
| Impax Asset Management Group plc | $16.277.700 | 435.000 | 0,51% | Aktien |
| Prosight Management, LP | $14.020.002 | 374.666 | 0,44% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13.991.714 | 373.910 | 0,44% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.685.018 | 365.714 | 0,43% | Aktien |
| BRAUN STACEY ASSOCIATES INC | $13.027.511 | 348.143 | 0,41% | Aktien |
| Fiera Capital Corp | $12.395.263 | 331.247 | 0,39% | Aktien |
| BANK OF AMERICA CORP /DE/ | $11.271.877 | 301.226 | 0,35% | Aktien |
| Defilade Capital Management, L.P. | $8.959.845 | 239.440 | 0,28% | Aktien |
| SEB Asset Management AB | $8.003.786 | 213.891 | 0,25% | Aktien |
| Foresite Capital Management VI LLC | $7.933.414 | 212.010 | 0,25% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $7.346.220 | 196.318 | 0,23% | Aktien |
| TD Asset Management Inc | $7.152.534 | 191.142 | 0,22% | Aktien |
| Swiss National Bank | $6.877.796 | 183.800 | 0,21% | Aktien |
| SEGALL BRYANT & HAMILL, LLC | $6.855.307 | 183.199 | 0,21% | Aktien |
| BlackRock, Inc. | $6.781.290 | 181.221 | 0,21% | Aktien |
| JENNISON ASSOCIATES LLC | $6.056.839 | 161.861 | 0,19% | Aktien |
| New Leaf Venture Partners, L.L.C. | $5.872.650 | 141.000 | 0,18% | Aktien |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5.865.136 | 156.738 | 0,18% | Aktien |
| Foresite Capital Management IV, LLC | $5.613.000 | 150.000 | 0,17% | Aktien |
| Bank of New York Mellon Corp | $5.581.754 | 149.165 | 0,17% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $5.508.898 | 147.218 | 0,17% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $5.471.384 | 146.216 | 0,17% | Aktien |
| Moody Aldrich Partners LLC | $5.466.201 | 146.077 | 0,17% | Aktien |
| Ishara Investments LP | $5.369.770 | 143.500 | 0,17% | Aktien |
| CITADEL ADVISORS LLC | $5.176.271 | 138.329 | 0,16% | Aktien |
| RHUMBLINE ADVISERS | $4.861.141 | 129.908 | 0,15% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $4.782.618 | 131.680 | 0,15% | Aktien |
| GordonMD Global Investments LP | $4.751.779 | 126.985 | 0,15% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4.712.974 | 125.948 | 0,15% | Aktien |
| JANUS HENDERSON GROUP PLC | $4.700.428 | 129.392 | 0,15% | Aktien |
| Cormorant Asset Management, LP | $4.677.500 | 125.000 | 0,15% | Aktien |
| SECTOR GAMMA AS | $4.289.380 | 114.628 | 0,13% | Aktien |
| XTX Topco Ltd | $4.164.547 | 111.292 | 0,13% | Aktien |
| ALPS ADVISORS INC | $3.981.825 | 106.409 | 0,12% | Aktien |
| FEDERATED HERMES, INC. | $3.957.390 | 105.756 | 0,12% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3.834.048 | 105.563 | 0,12% | Aktien |
| Nuveen Asset Management, LLC | $3.760.151 | 73.541 | 0,12% | Aktien |
| Burkehill Global Management, LP | $3.742.000 | 100.000 | 0,12% | Aktien |
| Nuveen, LLC | $3.619.262 | 96.720 | 0,11% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $3.484.251 | 93.112 | 0,11% | Aktien |
| MORGAN STANLEY | $3.320.829 | 88.744 | 0,10% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $3.266.729 | 87.299 | 0,10% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $3.254.754 | 86.979 | 0,10% | Aktien |
| AWM Investment Company, Inc. | $3.180.700 | 85.000 | 0,10% | Aktien |
| Odyssean, LLC | $3.160.344 | 84.456 | 0,10% | Aktien |
| Affinity Asset Advisors, LLC | $2.806.500 | 75.000 | 0,09% | Aktien |
| ALGERT GLOBAL LLC | $2.714.147 | 72.532 | 0,08% | Aktien |
| ExodusPoint Capital Management, LP | $2.652.404 | 70.882 | 0,08% | Aktien |
| Ensign Peak Advisors, Inc | $2.507.290 | 67.004 | 0,08% | Aktien |
| BARCLAYS PLC | $2.466.127 | 65.904 | 0,08% | Aktien |
| FIRST TRUST ADVISORS LP | $2.370.631 | 63.352 | 0,07% | Aktien |
| Man Group plc | $2.284.229 | 61.043 | 0,07% | Aktien |
| MetLife Investment Management, LLC | $2.258.709 | 60.361 | 0,07% | Aktien |
| CITIGROUP INC | $2.255.229 | 60.268 | 0,07% | Aktien |
| Longaeva Partners L.P. | $2.184.879 | 58.388 | 0,07% | Aktien |
| Swedbank AB | $2.155.392 | 57.600 | 0,07% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.068.016 | 55.265 | 0,06% | Aktien |
| Jump Financial, LLC | $1.923.388 | 51.400 | 0,06% | Aktien |
| Lighthouse Investment Partners, LLC | $1.871.000 | 50.000 | 0,06% | Aktien |
| Vestmark Advisory Solutions, Inc. | $1.823.252 | 48.724 | 0,06% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.787.254 | 47.762 | 0,06% | Aktien |
| VANGUARD GROUP INC | $1.774.626 | 38.123 | 0,06% | Aktien |
| Point72 Asset Management, L.P. | $1.735.577 | 46.381 | 0,05% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $1.696.398 | 45.334 | 0,05% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $1.606.254 | 42.925 | 0,05% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.549.188 | 41.400 | 0,05% | Kaufoption |
| Invesco Ltd. | $1.545.446 | 41.300 | 0,05% | Aktien |
| Vanguard Global Advisers, LLC | $1.485.986 | 39.711 | 0,05% | Aktien |
| HighMark Wealth Management LLC | $1.444.224 | 38.595 | 0,04% | Aktien |
| OAK RIDGE INVESTMENTS LLC | $1.405.046 | 37.548 | 0,04% | Aktien |
| Orion Porfolio Solutions, LLC | $1.404.234 | 37.526 | 0,04% | Aktien |
Unternehmensinsider 20 Insider · 9 Führungskräfte · 10 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10. März 2025 A | 52.000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26. September 2024 M | 111.092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19. März 2025 S | 87.491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12. Juni 2025 M | 99.713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19. März 2025 S | 72.233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10. Januar 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 5. Juli 2024 M | 29.259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17. Oktober 2023 M | 43.210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28. Februar 2022 A | 176.995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Direktor | 2. Juli 2026 S | 19.225 | 0 | 1 | $-120.000 |
| Caren Deardorf | Direktor | 18. Juni 2026 A | 22.225 | 0 | 0 | $0 |
| Weston Nichols | Direktor | 18. Juni 2026 A | 22.225 | 0 | 0 | $0 |
| Stephanie Okey | Direktor | 18. Juni 2026 A | 12.325 | 0 | 2 | $-246.143 |
| Matthew K Fust | Direktor | 18. Juni 2026 A | 28.761 | 0 | 0 | $0 |
| Camille L Bedrosian | Direktor | 18. Juni 2026 A | 22.225 | 0 | 0 | $0 |
| Wendell Wierenga | Direktor | 18. Juni 2026 A | 122.071 | 0 | 0 | $0 |
| Wendall Wierenga | Direktor | 11. Juni 2025 A | 116.146 | 0 | 0 | $0 |
| Stephen W Kaldor | Direktor | 19. Juni 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Direktor | 21. Juni 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 7. August 2026 M | 424.706 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 Einreichungen | 1. März 2024 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 55 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107.892 NS | 31. Mai 2026 | N-PORT |
| IHE · iShares Trust | 1,95% | 376.636 SH | 8. August 2026 | Täglich |
| FMED · Fidelity Covington Trust | 1,65% | 19.000 NS | 31. Mai 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4.666 NS | 30. April 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18.743 NS | 30. April 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11.043 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 0,63% | 718.323 SH | 8. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 5.737 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,54% | 940.202 SH | 8. August 2026 | Täglich |
| NUSC · Nushares ETF Trust | 0,28% | 93.045 NS | 30. April 2026 | N-PORT |
| ISCG · iShares Trust | 0,27% | 32.694 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,27% | 2.625.192 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,23% | 110.770 SH | 8. August 2026 | Täglich |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38.553 NS | 30. April 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3.872 NS | 31. Mai 2026 | N-PORT |
| ESML · iShares Trust | 0,16% | 55.438 SH | 8. August 2026 | Täglich |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3.142 NS | 30. April 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 51.135 SH | 8. August 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18.879 NS | 30. April 2026 | N-PORT |
| ISCB · iShares Trust | 0,13% | 4.625 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,12% | 596.648 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,12% | 42.391 NS | 30. April 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,11% | 1.399.667 SH | 8. August 2026 | Täglich |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31.759 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4.601 NS | 31. Mai 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,09% | 2.909 SH | 8. August 2026 | Täglich |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492.431 NS | 31. Mai 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24.991 NS | 30. April 2026 | N-PORT |
| WSML · iShares Trust | 0,07% | 5.742 SH | 8. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41.183 NS | 30. April 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196.549 NS | 30. April 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3.599 NS | 31. Mai 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,05% | 2.419.186 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,05% | 275.155 SH | 8. August 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5.196 NS | 30. April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.210.574 SH | 8. August 2026 | Täglich |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3.643 NS | 31. Mai 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5.689 NS | 31. Mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3.773 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31. Mai 2026 | N-PORT |
| ITOT · iShares Trust | 0,01% | 146.419 SH | 8. August 2026 | Täglich |
| IWV · iShares Trust | 0,01% | 27.043 SH | 8. August 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,01% | 125.853 NS | 30. April 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 3.342.704 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8.345 SH | 8. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,01% | 22.843 SH | 8. August 2026 | Täglich |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28.694 NS | 31. Mai 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5.863 NS | 30. April 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3.388 NS | 30. April 2026 | N-PORT |